Ascites News and Research

RSS
Portal vein hypertension diminishes after hepatitis C recovery

Portal vein hypertension diminishes after hepatitis C recovery

UCLA researchers find new way to reduce ascites with minimal side effects

UCLA researchers find new way to reduce ascites with minimal side effects

Replacing animal-derived antibodies with modern technologies can improve quality of research, reduce costs

Replacing animal-derived antibodies with modern technologies can improve quality of research, reduce costs

Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

BRCA gene mutations and ovarian cancer: an interview with Dr Matulonis, Harvard Medical School

BRCA gene mutations and ovarian cancer: an interview with Dr Matulonis, Harvard Medical School

Novogen's Anisina granted FDA Orphan Drug Designation for neuroblastoma

Novogen's Anisina granted FDA Orphan Drug Designation for neuroblastoma

Study shows that Anisina has potential to improve effectiveness of chemotherapy in children with cancer

Study shows that Anisina has potential to improve effectiveness of chemotherapy in children with cancer

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Salix Pharmaceuticals receives FDA approval for Xifaxan 550 mg to treat IBS-D in adults

Salix Pharmaceuticals receives FDA approval for Xifaxan 550 mg to treat IBS-D in adults

Pocket-sized ultrasound device reduce need for further testing in inpatient and outpatient settings

Pocket-sized ultrasound device reduce need for further testing in inpatient and outpatient settings

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Cantrixil drug granted FDA Orphan Drug Designation for treatment of ovarian cancer

Cantrixil drug granted FDA Orphan Drug Designation for treatment of ovarian cancer

Novogen appoints PCG Advisory to manage investor-awareness program in the US

Novogen appoints PCG Advisory to manage investor-awareness program in the US

Cantrixil proves highly effective at killing human ovarian stem cells in pre-clinical study

Cantrixil proves highly effective at killing human ovarian stem cells in pre-clinical study

Pre-clinical data on Novogen’s Cantrixil to be presented at two upcoming conferences

Pre-clinical data on Novogen’s Cantrixil to be presented at two upcoming conferences

Lilly receives FDA approval for CYRAMZA (ramucirumab)

Lilly receives FDA approval for CYRAMZA (ramucirumab)

Ashish Nimgaonkar wins AGA-Boston Scientific Career Development Technology & Innovation Award

Ashish Nimgaonkar wins AGA-Boston Scientific Career Development Technology & Innovation Award

Faster and more accurate method for testing new cancer drugs

Faster and more accurate method for testing new cancer drugs

FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

Innovative treatment option for children with plastic bronchitis

Innovative treatment option for children with plastic bronchitis